Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

BMT for severe autoimmune diseases: an idea whose time has come

R K Burt1

  • 1Northwestern University Chicago, Illinois, USA.

Oncology (Williston Park, N.Y.)
|July 1, 1997
PubMed
Summary

Severe autoimmune diseases (SADS) are rare but rapidly progressive, leading to early mortality. Early identification of SADS patients is crucial for initiating aggressive treatments like bone marrow transplantation (BMT).

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Autologous haematopoietic stem cell transplantation as a first-line disease-modifying therapy in patients with 'aggressive' multiple sclerosis.

Multiple sclerosis (Houndmills, Basingstoke, England)·2021
Same author

Cardiopulmonary assessment of patients with systemic sclerosis for hematopoietic stem cell transplantation: recommendations from the European Society for Blood and Marrow Transplantation Autoimmune Diseases Working Party and collaborating partners.

Bone marrow transplantation·2017
Same author

Remission of Crohn's disease after cord blood transplantation for leukocyte adhesion deficiency type 1.

Bone marrow transplantation·2013
Same author

Brazilian experience with two conditioning regimens in patients with multiple sclerosis: BEAM/horse ATG and CY/rabbit ATG.

Bone marrow transplantation·2009
Same author

T-cell clones persisting in the circulation after autologous hematopoietic SCT are undetectable in the peripheral CD34+ selected graft.

Bone marrow transplantation·2009
Same author

Autologous peripheral blood CD133+ cell implantation for limb salvage in patients with critical limb ischemia.

Bone marrow transplantation·2009

Area of Science:

  • Immunology
  • Rheumatology
  • Hematology

Background:

  • Autoimmune diseases typically have a normal life expectancy, leading to conservative treatment approaches.
  • A subset of patients experience severe autoimmune diseases (SADS) with rapid progression and high early mortality.
  • Identifying SADS patients early is critical to prevent irreversible organ damage.

Purpose of the Study:

  • To highlight the existence and characteristics of severe autoimmune diseases (SADS).
  • To emphasize the need for early identification of SADS patients.
  • To discuss the potential of aggressive interventions, such as immune ablation and hematopoietic stem-cell rescue (bone marrow transplantation [BMT]), for SADS.

Main Methods:

  • Review of clinical course and outcomes in patients with autoimmune diseases.
  • Identification of a subset of patients with severe, rapidly progressive disease (SADS).
  • Enrollment of SADS patients in experimental protocols involving immune ablation and bone marrow transplantation (BMT).

Main Results:

  • SADS are characterized by rapid progression and are associated with early mortality.
  • Experimental protocols involving immune ablation and bone marrow transplantation (BMT) are being utilized for SADS patients.
  • The long-term benefits of BMT for SADS remain to be determined due to its high cost and ongoing evaluation.

Conclusions:

  • Severe autoimmune diseases (SADS) represent a distinct, high-risk group requiring specialized management.
  • Early detection of SADS is paramount for timely intervention and potentially improved outcomes.
  • Bone marrow transplantation (BMT) is an experimental approach for SADS, with its efficacy and long-term benefits still under investigation.

Related Experiment Videos